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Abstract
We have recently found that thyroid transcription factor-1 (TTF-1), a homeodomain-containing transcription factor, is
postnatally expressed in discrete areas of the hypothalamus and closely involved in neuroendocrine functions. We now
report that transcription of cyclooxygenase-2 (COX-2), the rate limiting enzyme in prostaglandin biosynthesis, was inhibited
by TTF-1. Double immunohistochemistry demonstrated that TTF-1 was expressed in the astrocytes and endothelial cells of
blood vessel in the hypothalamus. Promoter assays and electrophoretic mobility shift assays showed that TTF-1 inhibited
COX-2 transcription by binding to specific binding domains in the COX-2 promoter. Furthermore, blocking TTF-1 synthesis
by intracerebroventricular injection of an antisense oligomer induced an increase of COX-2 synthesis in non-neuronal cells
of the rat hypothalamus, and resulted in animals’ hyperthermia. These results suggest that TTF-1 is physiologically involved
in the control of thermogenesis by regulating COX-2 transcription in the brain.
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Introduction
Thermoregulation is an essential component of the homeostatic
system to maintain body temperature during the febrile response
to infection and the challenge of low environmental temperature
[1]. Fever is a brain-regulated sickness response, which is triggered
by several peripheral signals, and mainly regulated by the
hypothalamus [2]. Circulating pyrogen-induced fever is mediated
by pro-inflammatory cytokines, such as tumor necrosis factor-a
(TNF-a), interleukin 1-b (IL 1-b) and IL-6 [3].
Prostaglandin E2 (PGE2) or its synthesis by action of cyclooxy-
genase(COX),aratelimitingenzymeforPGsynthesis,wasshownto
play a critical role in the fever response [4,5]. Two isoforms of COX
were found in the early 1990s, and named COX-1 and COX-2 [6].
COX-1 and COX-2 show a high sequence homology, but their
catalytic activities and expression patterns are markedly different
[7,8]. COX-1 is expressed constitutively in various cells and tissues
[9], while COX-2 expression is inducible in response to growth
factors, tumor inducers, hormones, and various inflammatory agents
in many cell types [10]. Fever invoked by various inflammatory
inducers was suppressed by COX-2-specific inhibitors or by
disruption of the COX-2 gene [4,11,12],and was strongly associated
with COX-2 expression in the brain endothelial cells [13].
In accordance with the notion of inducible expression of COX-
2, its promoter region contains a number of binding domains for
transcription factors [14], most of which are stimulatory. In the
brain, neuronal COX-2 is constitutive, while its expression in non-
neuronal cells is stimulated by pyrogen through the action of
nuclear factor kappa B [15,16]. In this study we have identified a
specific action of thyroid transcription factor-1 (TTF-1) for the
inhibition of COX-2 transcription in the rat hypothalamus and its
physiological role for fever control.
Though TTF-1 was first identified in the thyroid gland [17], it
was also reported as Nkx2.1 (a member of the Nkx family of
homeobox genes) essential for normal development of embryonic
diencephalon [18]. TTF-1 expression persists after birth in defined
glial and neuronal subsets of the forebrain [19]. Specifically, TTF-
1 was detected in some neuronal cells of the rat hypothalamus such
as neurons expressing gonadotropin releasing hormone (GnRH)
[19], pituitary adenylate cyclase-activating polypeptide (PACAP)
[20], and proopiomelanocortin (POMC) and agouti-related
peptide (AgRP) [21]. In addition to its neuronal expression,
TTF-1 was also expressed in non-neuronal cells in the postnatal
rat brain, such as ependymoglial cells of the third ventricle and
median eminence [19], in the tanycytes and/or astrocytic
tanycytes of the subfornical organ [22], and in the epithelial cells
of the choroid plexus [23].
We now report that TTF-1 binds to its binding domains in
COX-2 promoter and inhibits COX-2 transcription in non-
neuronal cells in the brain. In addition, obstruction of TTF-1
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neuronal cells and resulted in an increase in body temperature.
Results
Expression of TTF-1 in the non-neuronal cells of preoptic
area (POA)
Previously, our reports have shown that TTF-1 is expressed in
some non-neuronal cells in the rat brain, such as ependymoglial
cells, tanycytes and epithelial cells of the third ventricle,
subfornical organ and choroid plexus, respectively [19,22,23].
Therefore, in this study we tried to identify TTF-1 expression in
the COX-2 expressing non-neuronal cells. Because the endothelial
cells of blood vessel and astrocytes in the POA are important sites
of the formation of PGs by COX-2 action [13,24], we performed
double immunohistochemistry (IHC) using a TTF-1 antibody and
an antibody against von Willebrand factor (vWF), a marker for
endothelial cells of blood vessel or an antibody for glial fibrillary
acidic protein (GFAP), a marker for astrocytes, on the brain
sections from male rats. As shown in Fig. 1, TTF-1-immunore-
activity (ir) (Fig. 1A and D) is widely distributed in the cells
throughout the POA. Some cells showing TTF-1-ir also express
vWF-ir (Fig. 1B and C) or GFAP-ir (Fig. 1E and F), suggesting that
TTF-1 is expressed in some non-neuronal cells in the POA, such
as endothelial cells of blood vessel and astrocytes. A similar cellular
co-localization of TTF-1 and vWF or GFAP was observed in other
brain regions examined (data not shown).
Effect of intracerebroventricular (icv) injection of
antisense (AS) TTF-1 oligodeoxynucleotide (ODN) on
COX-2 expression in the hypothalamus
To determine whether in vivo inhibition of TTF-1 synthesis
affects COX-2 synthesis in the hypothalamus, we injected a well-
defined blocking system of TTF-1 synthesis [21,22,23], AS TTF-1
ODN, or its SCR (scrambled) sequence into the lateral ventricle of
male rats. One day after the injection, the hypothalamus was
collected for measurement of TTF-1 and COX-2 expression
levels. As shown in Fig. 2A, the AS TTF-1 ODN injection
effectively decreased the content of TTF-1 protein in the
hypothalamus, as determined by western blot analysis. This
reduction in TTF-1 protein level was accompanied by an
induction in COX-2 mRNA and protein in the hypothalamus
(Fig. 2B and C). POMC mRNA, negatively regulated by TTF-1
[21], was also increased by the AS TTF-1 ODN (Fig. 2D), further
indicating that the AS ODN is effective.
IHC results confirmed that the AS TTF-1 ODN clearly
decreased TTF-1-ir in the POA section (Fig. 2E, left), which
resulted in a dramatic increase of COX-2-ir (Fig. 2E, right). COX-
2-ir was rarely or never observed in the SCR ODN-injected
section, suggesting that its expression is strongly suppressed by
TTF-1 in this condition. Thus, we tried to colocalize COX-2 and
TTF-1 in the AS TTF-1 ODN injected rat POA. Though TTF-1-
ir was decreased by the AS TTF-1 ODN (as shown in Fig. 2C,
left), some cells positive to TTF-1-ir was also positive to the COX-
2-ir in the AS TTF-1 ODN injected condition (Fig. 2F), while no
double positive cell was observed in the SCR ODN injected
animals (data not shown). The AS TTF-1 ODN induced COX-2-
ir was localized in non-neuronal cells negative for neuron specific
nuclear protein (NeuN)-ir in the POA (Fig. 2G); whereas it showed
specific distribution in the cells located in blood vessel-like
structures (as identified by vWF in Fig. 1B and C). These data
suggest that blockade of TTF-1 synthesis induces non-neuronal
COX-2 expression in the endothelial cells of blood vessels in the
hypothalamus where is an important brain structure for the fever
response [13].
In agreement with a previous study [25], constitutive neuronal
COX-2-ir was observed in several brain regions, such as the
Figure 1. Expression of TTF-1 in non-neuronal cells of the POA. Double IHC was performed on brain sections derived from 2-month-old male
rats. TTF-1 protein (red, A, C, D and F) was detected with a monoclonal antibody. Endothelial cells of blood vessels (green, B and C) were identified
using antibody against vWF, an endothelial cell-specific marker. Astroglial cells (green, E and F) were determined using GFAP antibody. A, red
fluorescence signals representing TTF-1 immuno-positive cells in the POA. B, green signals revealing vWF-ir in the endothelial cells of blood vessel on
the same section with A. C, merged image of A and B showing some cells co-expressing TTF-1 and vWF (indicated as arrows). Inset highlighting
higher magnification image of TTF-1 colocalized with vWF. D and E, TTF-1 (red, D) and GFAP (green, E) immunoreactivities in cells of the POA.
F, merged image of D and E revealing some cells with colocalization of TTF-1 and GFAP (arrow). Higher magnification image in inset highlighting
colocalization of TTF-1 and GFAP. Scale bar=50 mm.
doi:10.1371/journal.pone.0028959.g001
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ODN and AS TTF-1 ODN treated animals, but no change to
COX-2-ir was found in these neuronal regions between the
treatments (Fig. S1). Interestingly, the AS ODN induced COX-2
expression only in the blood vessel cell-like structures (Fig. S1D, E,
G, and H), while COX-2-ir was absent in these structures of SCR
ODN-injected control (Fig. S1A and B). This might be due to
these cells expressing inducible non-neuronal COX-2 [26] which
is under inhibitory control of TTF-1. Though we were unable to
detect TTF-1-ir in these regions, a previous study reported TTF-1
expression in the cerebral cortex and hippocampus of the mouse
brain [27].
TTF-1 inhibits COX-2 transcription in non-neuronal cells
To confirm the inhibitory effect of TTF-1 on the transcription
of the COX-2 gene, we performed promoter assays using a
luciferase construct containing the rat COX-2 promoter region
(-2698 to +32) and a rat TTF-1 expression plasmid (TTF-1-
pcDNA) in C6 glioma and B35 neuroblastoma cells. COX-2
promoter activity was gradually decreased by addition of TTF-1
expression vector in a dose-dependent manner in C6 cells (Fig. 3A),
but did not show any change in the B35 cells (Fig. 3B). To further
confirm effect of TTF-1 on the endogenous COX-2 expression in
the C6 and B35 cells, we performed real-time PCR and western
blot analysis of samples extracted from the cells transfected with
TTF-1 expression vector. Overexpression of TTF-1 decreased
mRNA and protein levels of COX-2 in the C6 glioma cells (Fig. 3C
and E), but not in the B35 neuroblastoma cells (Fig. 3D and F). In
accordance with COX-2 expression, PGE2 release was also
decreased by TTF-1 only in the C6 cells (Fig. 3G and H).
Consistent with in vivo results shown above, results from
promoter assays, real-time PCR, and western blot analysis suggest
that TTF-1 exerts an inhibitory effect on COX-2 transcription
only in non-neuronal cells.
Figure 2. Effect of TTF-1 synthesis blockade on the COX-2 expression in the hypothalamus. The AS TTF-1 ODN or SCR ODN was injected
into the lateral ventricle of 2-month-old male rats. One day after the injection, the hypothalamus was collected for western blot and real-time PCR
analyses, or was examined by IHC. A, western blots showing a decrease in TTF-1 protein level caused by administration of the AS TTF-1 ODN (AS)
compared with SCR ODN. B and C, AS TTF-1 ODN significantly increased both COX-2 mRNA (B) and protein (C) levels determined by real-time PCR
analysis and western blotting. D, real-time PCR analysis showing increased POMC mRNA by the AS ODN (n=6). **, p,0.01 versus SCR. E, the POA
section showing a decrease of TTF-1-ir (red) and an increase of COX-2-ir (green) caused by the AS TTF-1 ODN. F, higher magnification images showing
co-localization of TTF-1-ir (red) and COX-2-ir (green) in the AS ODN injected rat POA. Note that COX-2-ir appears in some cells expressing TTF-1-ir
(merged, arrow). G, higher magnification images showing COX-2-ir (green) in the AS ODN injected rat POA. Notice that COX-2 is present only in cells
with an absence of the NeuN-ir (red). Scale bar=100 mm.
doi:10.1371/journal.pone.0028959.g002
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promoter
Electrophoretic mobility shift assays (EMSAs) were performed
to determine the ability of synthetic TTF-1 homeodomain (HD) to
recognize the putative TTF-1 binding sites present in the COX-2
promoter. Double-stranded ODN probes, containing the pre-
sumptive TTF-1 binding sites (Fig. S2) and their flanking
sequences, shown in Table 1, were employed. Of the 26 putative
binding sites, 20 were recognized by TTF-1 HD (Fig. 4A). The site
at 22039 showed the strongest signal that reached about 70% of
the positive control probe C. The sites at 22624, 22361, 22203,
22178, 21657, 2805, 2407 and 2223 revealed moderate
binding activity at least about 25% of probe C. Other putative
binding domains showed only very low or no binding activity.
To further determine in vivo interactions of TTF-1 with its
binding domains in the COX-2 promoter, chromatin immuno-
precipitation (ChIP) assays were performed using a TTF-1
antibody. The precipitated DNA was amplified using PCR primer
Figure 3. Regulation of COX-2 transcription by TTF-1. Luciferase reporter constructs (pGL2) containing 59-flanking region of the rat COX-2
gene were cotransfected into C6 glioma and B35 neuroblastoma cells with an expression vector carrying the rat TTF-1-coding region (TTF-1-pcDNA)
at the final concentrations indicated. The cells were harvested for luciferase and b-galactosidase assays 24 h after transfection. A, dose-dependent
inhibition of the COX-2 promoter activity by increasing concentrations of TTF-1 in C6 cells. Each value represents mean6SEM (n=6). ***, p,0.001
versus 0 ng. B, absence of TTF-1 effect on COX-2 promoter in B35 cells. C and D, data from real-time PCR analysis showing effect of TTF-1 (TTF-1-
pcDNA, 500 ng) on the endogenous COX-2 mRNA expression in the C6 cells (C) and B35 cells (D). E and F, data from western blotting revealing effect
of TTF-1 on the COX-2 protein in the C6 cells (E) and B35 cells (F). G and H, PGE2 release from C6 cells (G) and B35 cells (H) by overexpression of TTF-1.
Each value represents mean6SEM (n=6). **, p,0.01 versus pcDNA.
doi:10.1371/journal.pone.0028959.g003
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Interestingly, primer sets targeted to the positive TTF-1 binding
domains observed in EMSA (Fig. 4A) amplified fragments
encompassing each TTF-1 binding motif (TBD) in the COX-2
promoter region (Fig. 4B). However, PCR amplification, using
primer sets for the domains revealing no binding with TTF-1 HD
(Fig. 4A), did not generate any specific band (Fig. 4B).
To test whether the rat hypothalamic TTF-1 is able to
specifically interact with the COX-2 promoter, EMSAs were
performed with nuclear extracts from the rat hypothalamus, using
probe -2039 which showed the strongest binding activity (Fig. 4A).
Nuclear proteins from the rat hypothalamus strongly bound to the
22039 ODN probe (Fig. 4B). The interaction of the labeled probe
with hypothalamic nuclear proteins was reduced by addition of a
5- or 20-fold excess of unlabeled ODN C. In contrast, an ODN
probe carrying a mutated core TTF-1 binding sequence C (Cb)
unable to bind TTF-1 was ineffective. Pre-incubation of
hypothalamic nuclear proteins with a TTF-1 antibody delayed
the migration of the protein-DNA complex, indicating that TTF-1
was indeed part of this complex.
Essential TTF-1 binding sites for the transcriptional
inhibition of COX-2 gene
To determine whether the TTF-1 binding sites recognized by
EMSAs are functionally active, we selected 9 TTF-1 binding
motifs showing medium or strong binding activity in the EMSAs
(Fig. 4A) and deleted each of 59-CAAG-39 (or 59-CTTG-39) core
motifs from the binding domains, and examined the ability of
TTF-1 to inhibit the mutated COX-2 promoters in C6 cells
(Fig. 5). Deletion of the 22039 binding site (showing the strongest
binding activity) completely abolished the inhibitory effect of TTF-
1 on the COX-2 promoter activity, suggesting that the site at
22039 is the most important site for the regulation of COX-2
transcription by TTF-1. As shown in Fig. 5, deletion of some sites
(22203, 21657 and 2223) resulted in a partial reversion (about
70% to 85% of the control COX-2 promoter activity without
TTF-1) from the TTF-1-induced inhibition of the COX-2
promoter activity (40% of the control COX-2 promoter activity
without TTF-1). Combined deletions of the binding motifs at
22039, 21657 and/or 2223 sites resulted in a complete
disappearance of inhibitory TTF-1 action on the COX-2
promoter activity. Combined deletions including both 22039
and 21657 sites looked a little bit more effective than other
combinations. However, no significant change was observed when
other sites were deleted, suggesting that only part of the TTF-1
binding domains identified by EMSAs are functionally active.
Results from promoter assays demonstrate that TTF-1 is a
functionally active inhibitor of COX-2 transcription by binding to
its binding domains in the COX-2 promoter region.
Effect of TTF-1 synthesis blockade on the regulation of
body temperature
To determine if blocking TTF-1 synthesis in the brain exerts a
physiological change in whole body levels, we evaluated the body
temperature of rats icv injected with the AS TTF-1 ODN. A
blockade of TTF-1 synthesis by the AS ODN dramatically
increased body temperature beginning 2 h after the injection; this
increase continued the whole observation period (Fig. 6). To
further confirm whether the effect of the AS ODN on the body
temperature is caused by change in PG synthesis, rats were i.p.
injected with indomethacin, a COX inhibitor, 30 min prior to the
injection of AS TTF-1 ODN, and their body temperature was
observed. Indomethacin significantly mitigated the AS TTF-1
ODN-induced hyperthermia during the observation period (Fig. 6),
suggesting that the blockade of TTF-1 synthesis by the AS ODN
induces a fever response via decreasing the inhibitory action of
TTF-1 on COX-2 expression.
Discussion
This study demonstrates the inhibitory action of TTF-1 in the
control of inducible non-neuronal COX-2 in the brain, and its
effect on COX-2-induced fever. Our histological data revealed
that TTF-1 is expressed in some portion of the non-neuronal cells,
such as astrocytes and endothelial cells of blood vessels, the main
sites of inducible COX-2 expression in the POA. Promoter assays
showed that TTF-1 inhibits COX-2 transcription in the glial cells
but not in the neuroblastoma cells. In agreement with these in vitro
data, inhibition of TTF-1 synthesis resulted in an increased
expression of non-neuronal COX-2 in the hypothalamus, which
caused hyperthermia in the rats.
In earlier studies we have found that TTF-1 targets several
downstream genes such as GnRH, proenkephalin, angiotensino-
gen, aquaporin-1, ErbB-2, PACAP, POMC and AgRP in the
neuronal or non-neuronal cells in the rat brain [19,20,21,22,23].
Table 1. EMSA oligonucleotide probes.
Location in the promoter
region of COX-2 gene Probe sequences
C
* 59-CACTGCCCATCAAGTGTTCTTGA-39
Cb
+ 59-CACTGCCCAGTCACGCGTTCTTGA-39
22624 59- GGAAATTCAAGCAGCAGA-39
22540 59- AGCTTCTCAAGGAAACTT-39
22361 59- GAACCATCTTGATTTAGT-39
22331 59- ATATTCCCTTGTCATCAG-39
22203 59- AATTGCTCTTGTCCTCAA-39
22195 59- TTGTCCTCAAGGTCTAAG-39
22178 59- GTTTCTTCTTGAGTTCTT-39
22170 59- TTGAGTTCTTGTGTAACT-39
22039 59- TAAATTTCAAGGAGTCTG-39
22008 59- CCTATGCCTTGCTTTTCC-39
21900 59- CCTGAGACTTGCTCTGTA-39
21662 59- TGAGTACCTTGACAAGAG-39
21657 59- ACCTTGACAAGAGTGTGG-39
21549 59- CAGAAAACAAGAACTACT-39
21421 59- AAAGGGCCTTGGTGACAT-39
21075 59- TTCATGCCAAGAACGTAC-39
21032 59- TCATTTTCTTGTTTTACT-39
2911 59- TTATTATCAAGCAATGTT-39
2805 59- ATATCTTCTTGTAAACGT-39
2592 59- CCTGGGGCTTGCTAGGAC-39
2441 59- AGAGCAGCAAGCACGTCA-39
2407 59- GGAGAGGCAAGGGGATTC-39
2351 59- ACATTCTCTTGCTCCTCC-39
2284 59- AGCCAGTCTTGGAGCAGG-39
2223 59- CAGCTCTCTTGGCACCAC-39
223 59- TTAAAAGCAAGGTTCTCC-39
Each sequence represents the sense strand of probes; core TTF-1 binding motifs
are underlined.
*and + denote positive and negative control probes, respectively (see text).
doi:10.1371/journal.pone.0028959.t001
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presence of well conserved TTF-1 binding motifs in their 59-
flanking regions. Surprisingly, the COX-2 promoter has 26
putative TTF-1 binding sites. Among these multiple binding sites,
twenty were recognized by binding with the TTF-1 HD: one
relatively strong binding site (at 22039) and 8 sites showing
moderate binding activity. Four of 9 single deletions within the
aforementioned sites resulted in a significant reversion of the TTF-
Figure 4. EMSAs and ChIP assays. EMSAs were performed with double-stranded oligomer probes containing the putative TTF-1 binding sites
shown in Fig. S2 and table 1. A, relative binding activities calculated as a percentage of TTF-1 HD binding to the positive control probe C. Cb, negative
control probe carrying mutations in the TTF-1 binding domain (TBD). ND, not detectable. B, ChIP assays of rat COX-2 promoter DNA using TTF-1 Ab.
DNA was immunoprecipitated from C6 cells with TTF-1 Ab (TTF-1) or IgG (as a negative control), and was PCR-amplified with primer sets, shown in
Information S1, for COX-2 promoter fragments including TTF-1 binding sites indicated as numbers at TBD. Input represents the DNA extracted from
the C6 cells before immunoprecipitation. C, hypothalamic nuclear extracts were incubated with oligonucleotide probes containing 22039 TTF-1
binding site, in the presence (+) or absence (-) of 5- or 20-fold excess of cold oligonecleotide C and Cb and TTF-1 antibody (TTF-1 Ab) or preimmune
serum (Pre IS). Incubation of nuclear proteins with a TTF-1 Ab prior to the protein-DNA binding reaction delays (arrow S, supershift) the migration of
the protein-DNA complex (arrow B). F, free probe.
doi:10.1371/journal.pone.0028959.g004
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TTF-1 directly inhibits the COX-2 transcription by binding to
these recognition sites. The finding that the COX-2 promoter
contains several functional TTF-1 binding sites is not extraordi-
nary. In fact, others and we have already reported the presence of
a relatively high number of binding sites for TTF-1 [23,28] as
previously reported for other transcription factors [29,30].
Interestingly, TTF-1 inhibited COX-2 transcription only in C6
cells, but not in B35 cells. The C6 cell line originated from a
chemically induced rat brain tumor and expresses GFAP and
vimentin [31,32], which is a property of undifferentiated astrocytic
cell type [33]. B35 cells were derived from a neonatal rat brain
tumor displaying neuronal characteristics: showing membrane
excitability, expression of enzymes for neurotransmitters and
neuron-specific enolase [34]. Thus our results indicate that TTF-1
is a transcriptional repressor specific to non-neuronal COX-2.
Consistent with this notion, an in vivo blockade of TTF-1 synthesis
by AS TTF-1 ODN stimulated COX-2 expression only in non-
neuronal cells (likely endothelial cells of blood vessel) but not in
neuronal cells.
The brain is one of the few organs where COX-2 is expressed
constitutively. COX-2 expressing neurons have been observed in
the brain structures like the cortex, hippocampus and amygdale
[25]. However, during an immune challenge, non-neuronal cells
have been reported to be the main source of PGs through COX-2
action in the brain [13,35]. Studies using selective COX-2
inhibitors or COX-2-deficient mice suggest a critical role of
COX-2 as a mediator of fever induced by lipopolysaccharide
(LPS) [4,35,36]. Fever response is caused by PGE2 released mainly
from endothelial cells of the hypothalamic blood vessels [13].
PGE2 diffuses out of these endothelial cells into thermoregulatory
neurons in the POA, the center for body temperature control
[37,38]. Then, EP3 receptors mediate the pyretic action of PGE2;
mutant mice lacking this receptor do not develop fever after
administration of PGE2, IL-1 or LPS [5].
In this study, we demonstrated that the icv administration of AS
TTF-1 ODN not only increased expression of non-neuronal
COX-2 in the hypothalamus, but also elevated body temperature.
This increase was clearly reversed by pretreatment with a COX
inhibitor (indomethacin), indicating that COX-2 (and its end
Figure 5. Effect of site-specific deletion of TTF-1 binding core
motifs on the TTF-1-induced inhibition of COX-2 promoter
activity. TTF-1 expression vector (TTF-1-pcDNA, 500 ng) was cotrans-
fected with nine single mutants of the COX-2 promoter (COX-2-P)
deleted with core TTF-1 binding sites (showing relatively strong or
moderate binding with TTF-1 in EMSAs) or with combined mutants
deleted with 22039, 21657, and/or 2223 sites. Positions of the deleted
binding sites are indicated. The data are the means6SEM (n=4).
###, p,0.001 versus COX-2-P + pcDNA; *, p,0.05; ***, p,0.001 versus
COX-2-P + TTF-1-pcDNA.
doi:10.1371/journal.pone.0028959.g005
Figure 6. Effect of TTF-1 synthesis blockade by AS TTF-1 ODN on the change of body temperature. Body temperature was measured for
24 h after icv administration of AS TTF-1 ODN or SCR ODN. A, temperature began to increase 2 h after icv injection (arrow at 0 h) of the AS TTF-1 ODN
(AS) and remained high until about 20 h after the injection compared with SCR ODN injected group (SCR). To determine involvement of
prostaglandins in the AS-induced hyperthermia, rats were i.p.-injected with indomethacin (Indo) 30 min prior to the injection of the AS. Pretreatment
of Indo significantly reduced the AS-induced increase of body temperature. The shaded area indicates dark period. The values represent means6SEM
(n=6). B, mean temperature after the injection indicating a significant difference between groups. ***, p,0.001 versus SCR; ###,p ,0.001 versus
AS.
doi:10.1371/journal.pone.0028959.g006
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TTF-1 ODN.
To inhibit TTF-1 expression in vivo, we designed and applied an
AS TTF-1 ODN [20,21,22,23] in this study. Although icv
administration of the AS ODN may diffuse to areas adjacent to
the ventricular region, we demonstrated, using IHC and
immunoblot analysis, that injection of the AS ODN into the
lateral ventricle induced a marked decrease in TTF-1 availability
in the hypothalamus, and thus resulted in related changes in the
physiology, such as an increase of non-neuronal COX-2
expression and hyperthermia.
We have recently reported that hypothalamic TTF-1 was down-
regulated by administration of leptin, an adipocyte-derived
hormone, and was involved in the regulation of feeding behavior
via the melanocortin pathway [21]. Although the major function
of leptin in the hypothalamus is regulation of appetite, previous
studies showed that this cytokine-like peptide can directly regulate
inflammation via induction of COX-2 in brain endothelial cells
[39,40,41]. Another study showed that TNF-a, a major proin-
flammatory cytokine acting through COX-2, significantly de-
creased TTF-1 expression as well as formation of TTF-1-DNA
complexes in thyroid cells [42]. Therefore, TTF-1 may be an
additional novel pathway for the action of the aforementioned
proinflammatory cytokines on the regulation of COX-2 synthesis.
Further studies are obviously required to test this hypothesis.
In summary, our results show that non-neuronal COX-2 in the
hypothalamus is under transcriptional repression by TTF-1, a
homeodomain containing transcription factor, and this regulatory
mechanism plays an important role in the control of body
temperature.
Materials and Methods
Animals
Two-month-old male Sprague-Dawley rats (Daehan Animal
Breeding Company, Chungwon, Korea) were housed in a room
with a conditioned photoperiod (12-h light/12-h darkness, lights
on from 6:00 a.m. to 6:00 p.m.) and temperature (23–25uC) just
after arrival and allowed ad libitum access to tap water and pelleted
rat chow. Animal experiments were conducted in accordance with
the regulations of the University of Ulsan and the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals. The Institutional Review Board of University of Ulsan
approved the experimental procedures (permission number UOU-
2010-012).
DNA constructs
A luciferase reporter plasmid (pGL2; Promega, Madison, WI)
containing the rat COX-2 promoter (Fig. S2) (NCBI GenBank
database accession No. L11611) was kindly provided by Dr. Ojeda
(Oregon National Primate Research Center/Oregon Health and
Science University, Beaverton, Oregon). Mutant COX-2 promot-
er constructs carrying deletions of the TTF-1 binding sites were
generated using the QuikChange
TM site-directed mutagenesis kit
(Stratagene, La Jolla, CA) according to the manufacturer’s
instructions; the intended mutations were confirmed by sequenc-
ing analysis. The oligodeoxynucleotide primers used were (a) a
primer set for deletion of 22624 (sense primer, 59-CAT TGC
TGG AAA TTC AGC AGA AGA GGG C-39; antisense primer,
59-GCC CTC TTC TGC TGA ATT TCC AGC AAT G-39), (b)
a primer set for deletion of 22361 (sense primer, 59-GAG AGG
TTG AAC CAT ATT TAG TTT GGG AC-39; antisense primer,
59-GTC CCA AAC TAA ATA TGG TTC AAC CTC TC-39), (c)
a primer set for deletion of 22203 (sense primer, 59-CTG CCT
TTC AAA ATT GCT TCC TCA AGG TC-39; antisense primer,
59-GAC CTT GAG GAA GCA ATT TTG AAA GGC AG-39),
(d) a primer set for deletion of 22178 (sense primer, 59-GGT CTA
AGT TTC TTA GTT CTT GTG TAA CTC-39; antisense
primer, 59-GAG TTA CAC AAG AAC TAA GAA ACT TAG
ACC-39), (e) a primer set for deletion of -2039 (sense primer, 59-
GTC TTT AAA TTT GAG TCT GAA GG-39; antisense primer,
59-CCT TCA GAC TCA AAT TTA AAG AC-39), (f) a primer set
for deletion of 21657 (sense primer, 59-GAT TTG AGT ACC
TTG AAG TGT GGA TTT TTA C-39; antisense primer, 59-
GTA AAA ATC CAC ACT TCA AGG TAC TCA AAT C-39),
(g) a primer set for deletion of 2805 (sense primer, 59-GCC ATA
GCA TAT CTT TAA ACG TAA ACG TGG AC-39; antisense
primer, 59-GTC CAC GTT TAC GTT TAA AGA TAT GCT
ATG GC-39), (h) a primer set for deletion of 2407 (sense primer,
59-GGG GAG AGG GGG ATT CCC TTA GTT AG-39;
antisense primer, 59-CTA ACT AAG GGA ATC CCC CTC
TCC CC-3), (i) a primer set for deletion of 2223 (sense primer, 59-
GGG CGG TGC AGC TCT GCA CCA CTT TGG GC-39;
antisense primer, 59-GCC CAA AGT GGT GCA GAG CTG
CAC CGC CC-39).
Real-time PCR
RNA was isolated from the hypothalamus and cell lines using
TRI reagent (Sigma-Aldrich, St. Louis, MO). The isolated RNA
samples were reverse-transcribed and amplified using real-time
PCR with the following primer sets: COX-2 sense primer, 59-ACC
AGA GCA GAG AGA TGA AA-39; antisense primer, 59-GAG
AGA CTG AAT TGA GGC AG-39; POMC sense primer, 59-
GCT AGG TAA CAA ACG AAT GG-39; POMC antisense
primer, 59-GCA TTT TCT GTG CTT TCT CT-39; glyceral-
dehydes-3-phosphate dehydrogenase (GAPDH) sense primer, 59-
TGT GAA CGG ATT TGG CCG TA-39; and antisense primer,
59-ACT TGC CGT GGG TAG AGT CA-39. Real-time PCR was
carried out in capillaries of the DNA Engine Opticon Continuous
Fluorescence Detection System (MJ Research Inc., Waltham, MA)
for approximately 40 cycles as follows: at 94 for 30 sec, 56 for
30 sec, and 73 for 35 sec.
Western blotting
Protein from the hypothalamus was homogenized in T-PER
lysis buffer (Pierce Chemical CO., Rockford, IL) containing a
protease inhibitor cocktail (1 mM PMSF, 10 mg/ml leupeptin, and
3 mM aprotinin) and 1 mM sodium orthovanadate. Extracted
protein (15 mg) was separated by SDS-PAGE and was transferred
to a membrane by electrophoretic transfer. The membrane was
incubated with mouse anti-TTF-1 antibody (clone 8G7G3/1,
NeoMarkers, Fremont, CA) or rabbit anti-COX-2 antibody
(Cayman, Ann Arbor, MI). Immunoreactivity was detected with
an enhanced chemiluminescence kit (Amersham Biosciences, Little
Chalfont, UK).
Tissue preparation
Rats were deeply anesthetized with tribromoethanol (250 mg/
kg body weight; Sigma-Aldrich) and perfused transcardially with
100 ml of 0.1 M phosphate buffer (PB), pH 7.5 followed by
100 ml of 3% paraformaldehyde in 0.1 M PB. The brains were
removed and cryoprotected in 0.1 M PB with 20% sucrose
overnight at 4uC. The brains were placed into inert mounting
medium (OCT compound, Sakura, Torrance, USA) in plastic
moulds, transfered to precooled dry ice with ethanol and frozen.
Sections were cut 30 mm on a cryostat microtome. Sections were
stored at 280uC until ready for use.
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The brain sections were dried overnight at room temperature.
The dried sections were boiled in 10 mM citrate buffer, pH 6.0,
for 20 min and allowed to cool to room temperature for 30 min.
Sections were then incubated for 30 min at room temperature in a
blocking solution containing 3% skim milk and 0.3% Triton X-
100 in 0.1 M PB. After incubation, the sections were washed with
0.1 M PB, and incubated with primary antibodies [mouse anti-
TTF-1 antibody (1:400; NeoMarkers), rabbit anti-TTF-1 antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
COX-2 antibody (1:1000; Cayman Chemical), mouse anti-GFAP
antibody (1:1000; Clone G-A-5, Sigma-Aldrich), rabbit anti-vWF
antibody (1:500; Abcam, Cambridge, UK), and mouse anti-NeuN
antibody (1:1000; Millipore, Billerica, MA)] in blocking solution
for overnight. After incubation, the sections were washed with PB,
and incubated with biotin-conjugated secondary antibodies [anti-
mouse IgG (1:500; Vector Laboratories, Burlingame, CA) for
TTF-1 (NeoMarkers), NeuN, and GFAP and anti-rabbit IgG
(1:500; Vector Laboratories) for TTF-1 (Santa Cruz Biotechnol-
ogy), COX-2, and vWF] in blocking solution for 2 h. After being
washed with PB, the sections were incubated with avidin-
biotinylated HRP-complex (ABC, Vector Laboratories) for 2 h
and then reacted with Tyramide Signal Amplification system
(NEN Life Science, Boston, MA). For double immunofluorescence
detection, after generation of the first signals, sections were
incubated in 0.3% H2O2 for 30 min followed by three 10-min
washes in PB, and then the second signals were developed. After
processing, the sections were mounted with a cover slip and
photographed using fluorescence microscopy.
Cell culture and assays for luciferase activity
Rat neuroblastoma B35 cells and rat glioma C6 cells were
grown in DMEM supplemented with high glucose (4.5 g/L) and
10% fetal bovine serum at 37uC in a humidified atmosphere with
5% CO2. Twenty-four h after seeding the cells in 12-well plates,
they were transiently transfected with the rat COX-2 promoter-
luciferase reporter construct (COX-2-P) using Lipofectamine/
PLUS (Invitrogen Life Technologies, Gaithersburg, MD) along
with different concentrations of the expression vector pcDNA 3.1-
zeo (Invitrogen) containing the rat TTF-1 coding region (TTF-1-
pcDNA). Transfection efficiency was normalized by co-transfect-
ing the b-galactosidase reporter plasmid (pCMV-b-gal; Clontech,
Palo Alto, CA) at 20 ng/well. The transfected cells were harvested
24 h after transfection and used for luciferase and b-galactosidase
assays, as previously reported (20).
PGE2 measurement
Fifty microliters of collected medium from cultured C6 and B35
cells were used for analysis of PGE2 using a PGE2 EIA kit
(Cayman Chemicals) following the manufacturer’s instructions.
Both the samples and standards were assayed in parallel.
EMSAs
Expression and purification of the TTF-1 HD have already
been described [43]. Double-stranded oligodeoxynucleotides,
labelled at the 59 end terminal with
32P, were used as probes in
the gel-retardation assays. Sequences of used oligonucleotides are
shown in Fig. S2 and Table 1. The oligonucleotides C and Cb
were used as positive and negative control, respectively [44]. The
gel-retardation assay was performed by incubating protein and
DNA in a buffer containing 20 mM Tris-HCl (pH 7.6), 75 mM
KCl, 0.25 mg/ml BSA, 5 mM DTT, 50 g/ml calf thymus DNA,
10% glycerol for 30 min at room temperature. TTF-1HD was
used at 150 nM. Oligonucleotides were used at the concentration
of 5 mM. Protein-bound DNA and free DNA were separated on
native 7.5% polyacrylamide gel run in 0.5x TBE (1x
TBE=45 mM Tris/borate/1 mM EDTA), for 1.5 h at 4uC. Gels
were fixed and exposed to phosphoimager (GS525; Bio-Rad,
Hercules, CA). Signals corresponding to protein-bound and free
DNA were quantified by using the Multi-analyst software. Binding
of TTF-1HD to oligonucleotides of the COX-2 promoter was
expressed as a percentage of the TTF-1HD binding to the C
oligonucleotide. In competition experiments, cold oligonucleotides
were used at 5 and 20 fold excess of the labelled probe. To confirm
the presence of immunoreactive TTF-1 in nuclear extracts,
proteins were incubated with 3 ml of undiluted TTF-1 antibody
(NeoMarkers) for 30 min at room temperature before performing
binding reactions.
ChIP assay
After lysis of the C6 cells, nuclei were extracted and
resuspended with nuclear lysis buffer (50 mM Tris, pH 8.1,
10 mM EDTA, 1% SDS, and protease inhibitors). Chromatin was
sheared by sonication and diluted 5 fold in ChIP dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris,
pH 8.1, 167 mM NaCl, and protease inhibitors). The reactions
were incubated with 1 mg of antibodies against TTF-1 (Santa Cruz
Biotechnology) at 4uC for overnight. Immune complexes were
collected by reacting with 60 ml of the salmon sperm DNA/protein
A agarose for 1 h at 4uC, and then washed consecutively for 5 min
each with buffers (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris, pH 8.1) containing different concentration of salts
(150 mM–500 mM), and 0.25 M LiCl. DNA from the protein-
DNA cross-links was extracted by incubating the reactions with
solution (1% SDS, 0.1 M NaHCO3,1 0mg RNase, and 0.3 M
NaCl) at 65uC for 4 h and was further purified with phenol/
chloroform. PCR amplification was performed using 35 cycles of
94uC for 30 sec, 54uC for 30 sec and 72uC for 30 sec, proceeded
by 94uC for 5 min, and followed by 72uC for 10 min. Sequence
information about PCR primer sets for ChIP assays are presented
in Information S1.
Icv administration of AS TTF-1 ODN
To determine effect of blocking TTF-1 expression on COX-2
synthesis, a phosphorothioate AS TTF-1 ODN (GenoTech Corp.,
Daejeon, Korea) was delivered into the lateral ventricle (coordi-
nates: AP=1.0 mm caudal to the bregma; V=3.6 mm from the
dura mater; L=0.16 mm from the midline) of adult male rats.
The AS TTF-1 ODN used to disrupt TTF-1 synthesis (59-GAC
TCA TCG ACA TGA TTC GGC GTC-39) was directed against
the sequence surrounding the first ATG codon of TTF-1 mRNA
as previously reported (20). As a control, a scrambled sequence of
identical base composition was used (59-AGT CCT ACT CGG
TAC GTA TGC AGC-39). For the icv injection, the ODNs were
diluted to a final concentration of 0.5 nmol/ ml of artificial
cerebrospinal fluid [20], and injected into the lateral ventricle
using an infusion syringe pump (KDS 100; KD scientific,
Holliston, MA). The animals were euthanized 24 h after ODNs
injection, and brain tissues were prepared.
Measurements of body temperature
Abdominal temperature was measured in male Sprague-Dawley
rats using biotelemetry transmitters (Mini-Mitter, Bend, OR)
implanted into the abdominal cavity. Prior to surgery, rats were
anesthetized with tribromoethanol (250 mg/kg B.W., Sigma-
Aldrich). After a week of recovery, AS TTF-1 ODN and its
SCR ODN (2 nmol /4 ml, respectively) were injected with an
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recorded on top of the receivers (model RA 1000; Mini-Mitter). A
data acquisition system (Vital View; Mini-Mitter) was used for
automatic control of data collection and analysis. Body temper-
ature was recorded at 10-min intervals for 24 h after the injection
of ODNs.
Statistics
Student’s t-test was used for comparison of two groups.
Differences among more than three groups were analyzed by
one-way ANOVA with Dunnett’s multiple comparison post-hoc
tests.
Supporting Information
Figure S1 Localization of COX-2 protein in several
different structures of the rat brain. The SCR ODN (A–
C) or TTF-1 AS ODN (D–H) was injected into the lateral ventricle
of 2-month-old male rats. Brain sections containing the cerebral
cortex (A, D, G), hippocampus (B, E, H) and piriform cortex (C, F)
were incubated with COX-2 antibody alone (green, A–F) or
together with NeuN antibody (red, G, H). Only blood vessel-like
cells (closed arrow heads on D, E) revealed a clear change in
COX-2-immunoreactivity by the AS ODN. Double immunohis-
tochemistry revealed that these blood vessel-like cells are absent of
NeuN-immunoreactivity (closed arrow heads on G, H). Open
arrow heads indicating representative cells co-expressing COX-2-
and NeuN-immunoreactivities (G, H). Scale bar=100 mm.
(TIF)
Figure S2 Nucleotide sequence of 59-flanking region of
the rat COX-2 gene. To find possible TTF-1 binding motifs,
DNA sequences for the rat COX-2 gene (NCBI GenBank
database, accession No. L11611) were analyzed. Nucleotides are
numbered by assigning position +1 to the transcriptional start site
(indicated with arrow). Position of putative TTF-1 binding motifs,
59-CAAG-39 and 59-CTTG-39, are indicated (red and underlined).
Several transcription factor binding sites and TATA box, based on
sequence analysis, are also indicated (underline). NF-kB, nuclear
factor kappa B; C/EBPb, CCAAT/enhancer-binding protein
beta; CRE, cAMP response element.
(TIF)
Information S1 Primer sets for ChIP assays. The
following primer sequences were used for PCR amplification of
the indicated TTF-1 binding domains.
(DOCX)
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